Novartis Clozaril Blood Monitoring Requirements Relaxed By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA agrees to labeling change decreasing monitoring requirements for agranulocytosis to once monthly from twice a month. The agency asks Novartis to track agranulocytosis rates in the national registry.
You may also be interested in...
Novartis Sends “Dear Doctor” Letter On Clozaril
Clarification of white blood cell monitoring schedule is key concern of the letter.
Novartis Sends “Dear Doctor” Letter On Clozaril
Clarification of white blood cell monitoring schedule is key concern of the letter.
Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia
FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.